Asia
Shanghai RAAS Blood Products Advances Blood Clotting Disorder Drug to Phase Two
Shanghai RAAS Blood Products (SHE:002252) initiated a second-phase clinical trial for SR604 injection targeting congenital coagulation factor VII deficiency.The study will evaluate multiple-dose efficacy of SR604 levels administered every four weeks, according to a Thursday filing with the Shenzhen bourse.Shares of the blood products maker slid 1% in recent trade.
SHE:002252
